Clinical dosimetry results from Phase 1 studies of Radspherin® in ovarian and colorectal cancer demonstrate absorbed doses to normal organs well below values associated with toxicity risks The results are consistent with the favorable safety profile observed to date and support the further development of Radspherin® for treatment of peritoneal metastases Oslo, Norway, 11 August […]
Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx’s pipeline of therapies targeting sleep biology Represents the successful outcome of a multi-year scientific collaboration between AstronauTx and Saniona Saniona receives shares in AstronauTx with a value of US$5 million London, UK and Copenhagen, Denmark, 10 August 2026 – Saniona (OMX: SANION), a clinical-stage biopharmaceutical company […]
Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program […]
Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS B) today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation […]
New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution Additional €20.5m provides the runway to finalize the ongoing US […]
